Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

TRK Inhibitors Are a Safe, Effective Option in TRK Fusion-Positive Cancers

July 24th 2020

Clinical data shows that the TRK inhibitors entrectinib and larotrectinib induce high response rates with favorable toxicity profiles and central nervous system penetration, and are a viable treatment option for patients with advanced TRK fusion-positive cancers.

USC73 Score Predictive of OS in Uterine Serous Carcinoma

July 23rd 2020

A 73-gene proliferative transcriptomic signature was found to better predict overall survival outcomes and potentially be used to personalize treatment in patients with uterine serous carcinoma.

Dr. Roué on the Next Steps With TG-1701 in MCL

July 20th 2020

Gaël Roué, PhD, senior scientist at Josep Carreras Leukaemia Research Institute, discusses the next steps with the investigational BTK inhibitor TG-1701 in mantle cell lymphoma.

Metastatic HER2+ Breast Cancer Treatment Must Move to Personalized Approach

July 17th 2020

The optimal sequence of therapies for patients with metastatic HER2-positive breast cancer must be an individualized one, and should be dependent on the presence and/or level of central nervous system disease.

Pyrotinib Yields Promising Efficacy and Tolerability Among HER2-Altered Solid Tumors

July 16th 2020

The investigational TKI pyrotinib demonstrated encouraging antitumor activity and a manageable toxicity profile in patients with heavily pretreated HER2-mutant non–small cell lung cancer, as well as other advanced solid tumors harboring activating HER2 alterations.

Three Key ASCO Studies Showcase Targeted Advances

July 15th 2020

Molecularly targeted therapies showed practice-changing results for patients with biomarker-driven lung, colorectal, and ovarian cancers in phase 3 randomized clinical trial findings.

First of its Kind MMRF CureCloud Makes Way for Precision Medicine in Myeloma

July 13th 2020

In our exclusive interview, Dr. Cho and Dr. Ghobrial discuss the inspiration for the MMRF CureCloud, how it advances precision medicine, and the long-term goals of the study for patients and physicians alike.

Dr. Marshall on the Importance of Molecular Testing in Gastrointestinal Cancers

July 13th 2020

John L. Marshall, MD, discusses the importance of molecular testing in gastrointestinal cancers.

Dr. Pennell on Challenges With NGS in Lung Cancer

July 10th 2020

Nathan Pennell, MD, PhD, discusses challenges with next-generation sequencing in lung cancer.

Dr. Halmos on the Importance of Identifying Biomarkers in Advanced NSCLC

July 9th 2020

Balazs Halmos, MD, MS, discusses the importance of identifying biomarkers in advanced non–small cell lung cancer.

Müschen Named Inaugural Director of Center of Molecular and Cellular Oncology at Yale Cancer Center and Yale School of Medicine

July 9th 2020

Markus Müschen, MD, PhD, has been named the inaugural Director of the Center of Molecular and Cellular Oncology at Yale Cancer Center and Smilow Cancer Hospital.

Beyond Cancer Type: New Pan-Tumor Targets Emerge

July 7th 2020

The growing use of genomic profiling technologies will help promote the development of anticancer therapies based on molecular features of a tumor rather than the body site of origin.

Precision Medicine Should Play a Role in Population-Based Health Care

July 1st 2020

Precision medicine should be seen as being synergistic―or at a minimum additive―to population medicine.

Fakih Fleshes Out Perceptions on Pembrolizumab Approval in TMB-High Solid Tumors

June 30th 2020

Marwan G. Fakih, MD, discusses the June 2020 FDA approval of pembrolizumab for use in select patients with unresectable or metastatic solid tumors that are tumor mutational burden–high provides a potentially life-saving option to those who have exhausted all other available therapies.

DESTINY-Lung01 Data Position Trastuzumab Deruxtecan as Next Oncogene-Driven Therapy in NSCLC

June 29th 2020

Nathan A. Pennell, MD, PhD, discusses the significance of findings from the DESTINY-Lung01 trial in non–small cell lung cancer.

Dr. Rana on Germline Genetic Testing in Advanced Prostate Cancer

June 23rd 2020

Huma Q. Rana, MD, MPH, discusses germline genetic testing in men with advanced prostate cancer.

Utility of Minimally Invasive Plasma-Based NGS Expands in NSCLC

June 23rd 2020

Plasma-based next-generation sequencing continues to offer a minimally invasive, highly specific modality to identify patients with actionable alterations in non–small cell lung cancer.

Survivin Isoforms Detection Predicts a Potential Role in Tumor Biology

June 22nd 2020

Three main survivin isoforms demonstrated the ability to translocate to the surface of plasma membrane in multiple cell types, suggesting a targetable role as a molecular biomarker.

Guidelines Recommend Widespread Genetic Testing for Metastatic Prostate Cancer, Associated Family History Risk

June 18th 2020

The first multidisciplinary, consensus-driven framework for genetic testing in prostate cancer was borne out of the 2019 Philadelphia Prostate Cancer Consensus Conference, leading to the creation of comprehensive guidelines regarding the evaluation, management, and implementation therein.

FDA Approves Pembrolizumab for TMB-High Tumors

June 16th 2020

The FDA has approved pembrolizumab (Keytruda) to treat adult and pediatric patients with unresectable or metastatic solid tumors that are tissue tumor mutational burden–high (≥10 mutations/megabase) and have progressed following prior therapy and who have no satisfactory alternative treatment options.